Echoes of Nurofen Case

摘要

A further aggravating factor in the case,the ACCC said,was the fact that GSK and Novartis had failed to change their marketing strategy after Reckitt Benckiser in 2015 was ordered to pay a fine of AUD6.0m($4.1m)for”similar conduct.”Between 2011 and 2015,RB claimed that its Nurofen Specific Pain products were each formulated to specifically treat a particular type of pain,when they all contained the same active ingredient,ibuprofen lysine 342mg.